Free Trial

Sol-Gel Technologies Q4 2022 Earnings Report

Sol-Gel Technologies logo
$0.43 -0.01 (-2.54%)
(As of 12/20/2024 05:16 PM ET)

Sol-Gel Technologies EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.13
Beat/Miss
Missed by -$0.12
One Year Ago EPS
N/A

Sol-Gel Technologies Revenue Results

Actual Revenue
$0.10 million
Expected Revenue
$1.85 million
Beat/Miss
Missed by -$1.75 million
YoY Revenue Growth
N/A

Sol-Gel Technologies Announcement Details

Quarter
Q4 2022
Time
N/A

Conference Call Resources

The #1 Coin for November 2024 (Ad)

Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…

You can get access to the report by clicking here now…

Sol-Gel Technologies Earnings Headlines

Sol-Gel Technologies Reports Strong Q3 2024 Results
Sol-Gel announces 180-day extension to regain compliance with Nasdaq
The #1 Coin for November 2024
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
See More Sol-Gel Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sol-Gel Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sol-Gel Technologies and other key companies, straight to your email.

About Sol-Gel Technologies

Sol-Gel Technologies (NASDAQ:SLGL), together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

View Sol-Gel Technologies Profile

More Earnings Resources from MarketBeat

Upcoming Earnings